RNAC Q4 2025 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$947,000+224.8% YoY

Gross Profit

$00.0% margin

Operating Income

$22M2303.2% margin

Net Income

-$93M-9775.7% margin

EPS (Diluted)

$-3.46

QoQ Revenue Growth

+109.5%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$296M

Total Liabilities

$423M

Stockholders' Equity

-$126M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$947,000	-$759,000	+224.8%
Gross Profit	$0	-$759,000	+100.0%
Operating Income	$22M	-$27M	+181.6%
Net Income	-$93M	-$10M	-802.9%

Revenue Segments

Operating Segment

$1M100%